RESOURCE LIBRARY

Back Bay Life Science Advisors provides strategic and investment banking guidance and execution to global biopharma and medtech companies of all stages and sectors. With unique integration of life science strategy and investment banking, Back Bay enables global companies and investors to make informed decisions regarding product development, commercialization, franchising, licensing, partnering, M&A, divestitures and more. 

In 2023, Back Bay, together with DNB Bank, announced the DNB//Back Bay Partnership for Healthcare. This Partnership provides a full range of strategic and financing capabilities for healthcare companies, including strategy, equity and debt capital markets, M&A and resources. Our combination of expertise spans more than 110 years and 1,000+ successful projects and transactions.

Our global healthcare team consists of more than 100 experienced investment and corporate bankers who work alongside seasoned healthcare strategic advisors.

We are a team of 100 with 1 mission - moving healthcare ahead.

 

 

CAPABILITIES


ABOUT BACK BAY LIFE SCIENCE ADVISORS

Strategic Capabilities Overview

Learn about our strategic and investment banking capabilities for life science companies and their investors.


ABOUT DNB//BACK BAY

Strategic and Financing Overview

Learn about DNB//Back Bay’s essential strategic and financial support for healthcare companies.


BROCHURE

About DNB//Back Bay

Learn about the DNB//Back Bay Partnership, including our healthcare strategy, corporate banking, debt and investment banking solutions


PRESENTATION

IPOS with DNB//Back Bay

Lean about DNB//Back Bay’s IPO capabilities in the US and Nordic markets - Coming Soon


INDUSTRY INSIGHTS


BACK BAY WHITEPAPER

The Radiopharmaceutical Renaissance

Despite an overall downturn in the biotech market in the 2022-2023 timeframe, the strategic and VC activity within the radiopharmaceutical space has remained relatively strong. Indeed, the average raise for radiopharma sponsors in 2023 was $51M, which eclipsed that of 2022, $38M


BACK BAY ARTICLE

Emerging Trends in Cell Technology

The ability to facilitate the growth and expansion of mammalian cells in vitro has been at the backbone of a wave of therapeutic innovations in the biotech space. Increasingly the know-how, materials, and equipment to harness cells as factories to produce complex proteins for therapeutic uses is being directed toward consumer applications. 

 

Please visit Back Bay’s website for more industry whitepapers, articles and podcasts.